High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis by Eyre, Steve et al.
 High density genetic mapping identifies new susceptibility loci for
rheumatoid arthritis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Eyre, S., J. Bowes, D. Diogo, A. Lee, A. Barton, P. Martin, A.
Zhernakova, et al. 2012. “High density genetic mapping identifies
new susceptibility loci for rheumatoid arthritis.” Nature genetics
44 (12): 1336-1340. doi:10.1038/ng.2462.
http://dx.doi.org/10.1038/ng.2462.
Published Version doi:10.1038/ng.2462
Accessed February 19, 2015 1:51:09 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11708546
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
High density genetic mapping identifies new susceptibility loci
for rheumatoid arthritis
Steve Eyre1,2,24, John Bowes1,2,24, Dorothée Diogo3,4,5,24, Annette Lee6, Anne Barton1,2,
Paul Martin1,2, Alexandra Zhernakova7,8, Eli Stahl3,4,5, Sebastien Viatte1,2, Kate
McAllister1,2, Christopher I. Amos9, Leonid Padyukov10, Rene E.M. Toes7, Tom W.J.
Huizinga7, Cisca Wijmenga8, Gosia Trynka3,4,5,8, Lude Franke8, Harm-Jan Westra8, Lars
Alfredsson11, Xinli Hu3,4,5,12, Cynthia Sandor3,4,5, Paul I.W. de Bakker3,4,5,13,14, Sonia
Davila15, Chiea Chuen Khor15, Khai Koon Heng15, Robert Andrews16, Sarah Edkins16,
Sarah E Hunt16, Cordelia Langford16, Deborah Symmons1,2, Biologics in Rheumatoid
Arthritis Genetics and Genomics Study Syndicate17, Wellcome Trust Case Control
Consortium17, Pat Concannon18, Suna Onengut-Gumuscu18, Stephen S Rich18, Panos
Deloukas16, Miguel A. Gonzalez-Gay19, Luis Rodriguez-Rodriguez20, Lisbeth Ärlsetig21,22,
Javier Martin23, Solbritt Rantapää-Dahlqvist21,22, Robert Plenge3,4,5,25, Soumya
Raychaudhuri1,2,3,4,5,25, Lars Klareskog10,25, Peter K Gregersen6,25, and Jane Worthington*,
1,2,25
1Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research , University of
Manchester, Manchester Academic Health Science Centre 2National Institute for Health
Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University
Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre. 3Division of
Rheumatology, Immunology, and Allergy Brigham and Women’s, Hospital, Harvard Medical
School, Boston, Massachusetts, 02115, USA 4Division of Genetics, Brigham and Women’s,
Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA. 5Program in Medical and
Population Genetics, Broad Institute, Cambridge, Massachusetts, 02142, USA. 6The Feinstein
Institute for Medical Research, North Shore–Long Island Jewish Health System, Manhasset, New
York, USA. 7Department of Rheumatology, Leiden University Medical Centre, Leiden, The
Netherlands. 8Department of Genetics, University Medical Center Groningen and University of
Groningen, Groningen, The Netherlands. 9University of Texas M.D. Anderson Cancer Center,
Houston, Texas, USA. 10Rheumatology Unit, Department of Medicine, Karolinska Institutet and
Karolinska University Hospital Solna, Stockholm, Sweden. 11Department of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden 12Harvard-MIT Division of Health Sciences
and Technology, Boston, Massachusetts 13Department of Epidemiology, University Medical
Center Utrecht, Utrecht, The Netherlands 14Department of Medical Genetics, University Medical
Center Utrecht, Utrecht, The Netherlands 15Division of Human Genetics, Genome Institute of
Singapore , Singapore. 16The Wellcome Trust Sanger Institute, Cambridge, UK 18Center for
Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA. 19Department of
17A list of members is provided in the Supplementary Note.
*Correspondence should be addressed to J.W (jane.worthington@manchester.ac.uk)..
24These authors contributed equally to this work.
25These authors supervised the work equally
Author Contributions J.W, P.K.G, L.K, S.R, R.P and S.E led the study. S.E, J.B, J.W, R.P and S.R wrote the paper. J.B, E.S, S.V,
A.Z, P.M, P.I.W.deB, C.I.A, K.Mc, and D.D performed the data and statistical analysis. , A.L, A.B, L.P, R E.M.T, T.W.J.H, C.W,
G.T, L.F, H-J.W , L.A, X.H , C.S , S.D, C.C.K, K.K.H, R.A, S.Ed, S.E.H, C.L, D.S, P.C, S.O-G, S.S.R, P.D, M.A.G-G, L.R-R, L.Ä,
J.M and S.R-D contributed primarily to the patient ascertainment, sample collection and/or genotyping. All authors reviewed the final
manuscript.
Competing financial interest None
Europe PMC Funders Group
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2013 June 01.
Published in final edited form as:
Nat Genet. 2012 December ; 44(12): 1336–1340. doi:10.1038/ng.2462.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Rheumatology, Hospital Marques de Valdecilla, IFIMAV, Santander, Spain. 20Hospital Clinico San
Carlos, Madrid, Spain. 21Departments of Public Health and Clinical Medicine Umeå University,
Umeå, Sweden 22Rheumatology, Umeå University, Umeå, Sweden 23Instituto de Parasitología y
Biomedicina López-Neyra, IPBLN-CSIC, Avenida del Conocimiento s/n, Granada, 18100, Spain.
Summary
Using the Immunochip custom single nucleotide polymorphism (SNP) array, designed for dense
genotyping of 186 genome wide association study (GWAS) confirmed loci we analysed 11,475
rheumatoid arthritis cases of European ancestry and 15,870 controls for 129,464 markers. The data
were combined in meta-analysis with GWAS data from additional independent cases (n=2,363)
and controls (n=17,872). We identified fourteen novel loci; nine were associated with rheumatoid
arthritis overall and 5 specifically in anti-citrillunated peptide antibody positive disease, bringing
the number of confirmed European ancestry rheumatoid arthritis loci to 46. We refined the peak of
association to a single gene for 19 loci, identified secondary independent effects at six loci and
association to low frequency variants (minor allele frequency <0.05) at 4 loci. Bioinformatic
analysis of the data generated strong hypotheses for the causal SNP at seven loci. This study
illustrates the advantages of dense SNP mapping analysis to inform subsequent functional
investigations.
Rheumatoid arthritis is a common, complex disease affecting up to 1% of the adult
population. It is an archetypal autoimmune disease, typified by the presence of serum
autoantibodies, including antibodies directed against the Fc portion of immunoglobulins
(rheumatoid factor) and against citrullinated peptides (anti-citrillunated peptide antibodies
(ACPA)). Genetic studies of rheumatoid arthritis, including recent application of genome
wide association studies (GWAS), have identified 32 risk loci among individuals of
European ancestry, including HLA-DRB1, PTPN22, and other loci with shared autoimmune
associations1, 2.
The Immunochip Consortium was formed to design a custom Illumina Infinium array that
leveraged the remarkable genetic overlap of susceptibility loci identified across a range of
autoimmune diseases. The custom array allows investigators to perform gene-finding and
fine-mapping experiments in a co-ordinated manner. Full details have been described
previously3. Briefly, the array consisted of all known single nucleotide polymorphisms
(SNPs) from the 1000 Genomes Project as well as private resequencing efforts for 186 loci,
known to be involved in 12 autoimmune diseases. For these loci there is the unique
opportunity to fine map autoimmune disease associations. Additional SNPs were included as
part of a deep replication effort. This not only provided the opportunity to identify novel
rheumatoid arthritis associations with other autoimmune disease loci or with variants with
suggestive statistical evidence for association from a previous meta-analysis of but also to
refine the GWAS signal and reduce the number of potential causal variants in the 31 non-
HLA confirmed loci.
We tested 129,464 polymorphic markers passing quality control, with a minor allele
frequency >1%, in 11,475 cases (7,222 ACPA positive, 3,297 ACPA negative and 957
unassigned) and 15,870 controls (Table 1 and Supplementary Tables 1 and 2). We
performed analysis on the total rheumatoid arthritis dataset, and also in subsets stratified by
ACPA status (Supplementary Table 3). We also had access to GWAS data for an additional
2,363 ACPA positive cases and 17,872 controls, independent of the current study (Table 1).
We observed strong evidence of association for the previously identified susceptibility loci
(Table 2 and Supplementary Tables 3 and 4).
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We identified fourteen novel rheumatoid arthritis loci for populations of European ancestry
(TYK2, IRAK1, TLE3, RASGRP1, PADI4, IL6R, IRF8, ARID5B, IKZF3, RUNX1,
POU3F1, RCAN1, CD5, GATA3) at genome-wide levels of significance (p<5×10−8)(Figure
1): 7 with Immunochip data alone (Table 2) and a further 7 when Immunochip data was
combined with the GWAS meta analysis data (Table 2). These loci add 4% to the estimate
of heritability explained by confirmed loci, bringing the total to 51%, of which HLA
explains 36%. When we removed all known loci from the Immunochip data, we still
observed evidence of an excessive number of nominally associated alleles, consistent with
the possibility that there are many additional undiscovered alleles 4(Supplementary Figure
1). Interestingly, if a study-wide significance threshold of 9.0×10−7 is applied (calculated
based on the number of effective independent tests when accounting for linkage
disequilibrium (LD)), significant association is also observed at two additional loci; ELMO1
(rs75351767 pall=2.94×10−7) and BACH2 (rs72928038 Pall = 8.23×10−7) (Supplementary
Table 3). A further 8 loci are implicated at suggestive levels of significance (p<1 ×10−5) in
either the full or ACPA positive sub-group analysis including PTPN2 (rs62097857
Pall=4.4×10−6); TNIP1 (rs6579837 Ppos=1.7×10−6) and TNFSF4 (rs61828284
Ppos=5.4×10−6) (Supplementary Table 3).
Previously, we have fine-mapped MHC associations observed in GWAS data of partially
overlapping samples by applying imputation of HLA classical alleles and amino acids5. The
Immunochip platform includes denser SNP coverage within the MHC region which
facilitates more accurate imputation. In a preliminary analysis applying the same imputation
and fine-mapping approach to ACPA positive cases and controls typed on Immunochip, we
observed the same associations that we reported previously. The most significant
polymorphic nucleotide was again rs17878703, mapping to position 11 of the HLA-DRB1
peptide sequence (p<10−677). Testing individual amino acid positions within HLA-DRB1
revealed the strongest association at position 11 (p<10−745); conditioning on the position 11
effect we observed association at position 71 (p=6×10−60); finally conditioning on effects at
both positions 11 and 71 we observed significant association at position 74 (p=7×10−19).
Adjusting for all HLA-DRB1 alleles to identify independent effects outside this gene we
observed significant associations at HLA-B corresponding to the presence of aspartate at
position 9 in the peptide sequence (p=1×10−17). Adjusting for all HLA-DRB1 alleles and
Asp-9 in HLA-B, we observed associations at HLA-DPB1 corresponding to the presence of
phenylalanine at position 9 in the peptide sequence (p=1×10−17).
While it has been demonstrated that ACPA positive and ACPA negative disease has a
different allelic association at the MHC and at PTPN22 6, previous studies have not been
powered to address this issue definitively in additional non MHC loci. Here we analysed
3,297 ACPA negative cases and identify association at genome wide significance to
ANKRD55 (rs71624119 p=5.2 ×10−12, OR=0.78) in addition to HLA (rs4143332
p=2.9×10−15, OR=1.37) (Supplementary Table 3). Strikingly, ANKRD55 has a similar
effect as in ACPA positive disease. Comparing association in ACPA positive and negative
subgroups we see that for the 45 non-HLA loci, around half show a significantly larger
effect size in ACPA positive disease (comparison of OR p<0.05), 5 of these loci having a
markedly stronger association with this form of disease (PTPN22, CCR6, CD40, RASGRP1
and TAGAP). Eleven loci show no statistical difference in association to either form of
rheumatoid arthritis (Supplementary Table 5).This preliminary analysis indicates that
differences in the serological subtype of disease may well be reflected in a difference in
genetic pre-disposition potentially providing a basis for stratified medicine.
The majority of the 14 new loci associated with rheumatoid arthritis susceptibility, along
with previously confirmed loci, were found to contain proteins strongly linked to immune
function using GRAIL analysis (Supplementary Table 6 and Supplementary Figure 2), for
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example, CD5, IRF8 and TYK2. We also report novel association with IRAK1, previously
associated with systemic lupus erythematosus (SLE)7. This is the first X chromosome locus
association to rheumatoid arthritis, and is of relevance given the female predominance of
both diseases (9:1 and 3:1 ratio of females: males in SLE and rheumatoid arthritis,
respectively). Interestingly, this locus has been shown to occasionally escape X inactivation
in female cells8. Three of the novel loci confirmed here for the first time in samples of
European ancestry have previously been associated in either samples of East Asian ancestry
(PADI4, ARID5B) or when using a multiethnic approach (IKZF3)9-11. The SNPs associated
in this study are moderately correlated with those identified in samples of East Asian origin,
PADI4 SNPs rs2240336 and rs766449 r2=0.25, D′=1; ARID5B SNPs rs12764378 and
rs10821944 r2=0.52, D′=0.86. PADI genes are involved in the citrullination of peptides and
as such are strong candidates for involvement in disease, given the presence of ACPA auto-
antibodies. Although the association at PADI4 (rs2240336) is greater in ACPA positive
disease (OR=0.88 P=6.49×10−9) compared to ACPA negative cases (OR=0.93, P=0.01) our
formal test comparing OR did not show a statistically significant difference (P=0.14).
We applied conditional logistic regression to test for secondary effects within each locus. In
6 non-HLA loci (13%) (TNFAIP3, CD28, REL, STAT4, TYK2, RASGRP1) we observed
additional independent association signals (Supplementary Figure 3). In total we observed
51 independent risk alleles in 45 non-HLA rheumatoid arthritis loci. To test the possibility
that the two risk alleles tag an untyped SNP, we carried out haplotype analysis of the six loci
but found no evidence for haplotype specific effects at any locus (Supplementary Table 7).
At only four loci, REL, CD28, TYK2 and TNFAIP3, did we observe associations with low
frequency variants (MAF<0.05) (Supplementary Table 8).
Out of the 46 rheumatoid arthritis loci, 39 were densely genotyped by Immunochip. For 12
loci we observed that the most strongly associated SNP was not tightly linked to the
previously reported leading SNP at that locus, shifting the association signal (Supplementary
Table 9). For the 39 confirmed non-HLA rheumatoid arthritis loci on Immunochip, dense
mapping refines the association to a single gene for 19 loci (Supplementary Table 10).
Our analysis also identified 7 non-synonymous SNPs within exonic regions (Table 3), as
well as a number showing strong regulatory potential (Supplementary Table 11), that are
highly correlated (r2>0.9) with the lead SNP and which are strong candidates for the
aetiological variant. The most associated SNP at the IL6R locus (rs8192284) is non-
synonymous, shows high correlation with circulating IL6R levels and as well as being
associated with a decrease risk of coronary heart disease12, 13, is in strong LD (r2=0.97, D
′=1) with the SNP recently reported to be associated with asthma (rs4129267)14.
Interestingly, the risk allele at the asthma associated SNP (OR=1.09, p=2.4×10−8) is
protective for rheumatoid arthritis (OR=0.9, p = 1.3×10−8). The IL6R ligand, IL6, is the
target of the biologic drug, tocilizumab, which has been shown to be an effective treatment
for rheumatoid arthritis. Abatacept is another biologic drug, with therapeutic efficacy in
clinical trials and which targets another rheumatoid arthritis susceptibility gene, CTLA4.
These examples highlight the potential for targeting genes within risk loci.
Testing for statistical interactions between the 46 lead SNPs in confirmed rheumatoid
arthritis loci, revealed preliminary evidence for 6 significant pairwise interactions, after
Bonferroni correction (p<5×10−4) (Supplementary Table 12). The GATA3-PRKCQ
interaction is supported by earlier biological observations15.
From 38 rheumatoid arthritis associated SNPs or proxies accessed for eQTL analysis, 18
showed an eQTL effect on at least one probe, giving a total of 51 SNP-probe combinations
with significant eQTL effect (Supplementary Table 13). From these 18 SNPs, 11 showed an
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independent or primary eQTL effect on one or more probes (20 SNP-probe combinations),
whereas 7 SNPs were not significant after conditioning of the strongest eQTL signal in the
locus.
Using a previously described approach, we assessed whether the 46 independent rheumatoid
arthritis associated regions, defined by previously known and novel SNP associations
discovered here, harboured genes that were specifically expressed in distinct immune cell-
types16. We observed in a large expression data set of 223 sorted mouse immune cells17,
that these regions contained genes that were most significantly more specifically expressed
in CD4+ effector memory T-cell subsets (p<10−7) (Supplementary Figure 4).
Of the diseases sharing susceptibility loci with rheumatoid arthritis, systematic fine mapping
has only been published, to date, for celiac disease3. Previously the two diseases were found
to share 6 confirmed non-HLA loci (MMEL, REL, CD28/CTLA4, TNFAIP3, TAGAP and
IL2/21) 2; Immunochip data now identifies an additional 4 confirmed loci common to both
diseases (DDX6, STAT4, PRKCQ and IRAK1) and a further 4 potential rheumatoid arthritis
loci (BACH2, p=8.2×10−7, ELMO1, p=2.9×10−7, PTPN2, p=4.4×10−6, PVT1, p=2×10−5) in
common with confirmed celiac disease loci (Supplementary Table 14). Of the ten
rheumatoid arthritis/celiac disease loci, 4 share the same lead SNP (CD28, IL2_21,
TNFAIP3 and IRAK1) and a fifth (MMEL1) shares highly correlated SNPs (r2>0.88) and,
for all of these variants, the risk allele is the same for both diseases. For two loci (PRKCQ
and DDX6), the lead SNPs are only moderately correlated (r2>0.62) with the minor allele
being protective in both diseases. The effects in STAT4 appear quite different with 3
independent effects in celiac disease and two different independent associations in
rheumatoid arthritis. The strongest association signal for risk of celiac disease at TAGAP is
with the minor allele of a SNP (rs182429) in moderate LD (r2=0.44) with the rheumatoid
arthritis risk SNP (rs629326). Indeed, when considering overlap of rheumatoid arthritis
susceptibility loci with other autoimmune diseases, only the PADI4 and CCL21 non-MHC
loci currently show unique association, suggesting that they may be important in
determining that the autoimmune reaction is directed at synovial joints.
In summary, through fine mapping on a custom made array designed to capture variation
across a number of loci associated with autoimmune diseases, we have identified 14 novel
European ancestry rheumatoid arthritis loci; refined the peak of association to a single gene
at 19 loci, identified 7 SNPs which might potentially be functional, found independent
effects at 6 loci and detected association with SNPs with low MAF (<0.05) at 4 loci. In one
third of cases, imputation of GWAS signals without fine-mapping, would have implicated a
different genetic region as being disease causal thus illustrating the importance of dense fine
mapping analysis prior to embarking on expensive functional studies.
Methods
Genotyping
All samples were genotyped for the Immunochip custom array in accordance with Illumina
protocols at six centres: UK (Sanger Centre, Hinxton, Cambridge, UK and the University of
Virginia, USA), US and Spain (Feinstein Institute, New York, USA), Sweden EIRA (The
Genome Institute, Singapore), Sweden Umea (Department of Medical Sciences, SNP&SEQ
Technology Platform, Uppsala University Hospital, Uppsala, Sweden) and The Netherlands
(Department of Genetics, University Medical Centre Groningen).
Genotype calling and quality control
Genotype calling was performed on all samples at The University of Manchester as a single
project using the Genotyping Module (v1.8.4) of the GenomeStudio Data Analysis Software
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package. Initial genotype clustering was performed using the default Illumina cluster file
(Immunochip_Gentrain_June2010.egt) and manifest file
Immuno_BeadChip_11419691_B.bpm (NCBI build 36) using the GenTrain2 clustering
algorithm. Poor performing samples (call rate < 0.90), labelled duplicates (selection
informed by 10th percentile GenCall score (p10 GC)) and samples identified post-
genotyping as inappropriate for inclusion were also excluded at this point (Supplementary
table 1). Automated reclustering was performed on all remaining samples to calibrate
clusters on the study sample set.
Poor quality assays were excluded prior to downstream quality control processes by
extensive manual review of clustering performance. A subset of good quality SNPs was
identified based on the ranking of quality metrics: cluster separation (<0.4), signal intensity
(<1.0), call rate (<0.98) and allele frequency. In addition, SNPs that mapped to the Y
chromosome or mitochondria, were non-polymorphic, were duplicates, or zeroed in the
default Illumina cluster file were also excluded. This resulted in a dataset of 165,549 good
quality SNPs (Supplementary Table 2).
To facilitate the meta-analysis and reduce differential missingness each of the six population
datasets were processed as discrete entities. SNPs were excluded from each of the datasets
with a call rate < 0.99 (cases or controls), a MAF < 0.01 or if they deviated from HWE (p <
5.7×10−7). Samples were excluded with a call rate < 0.99 or if they were identified as
outliers based on autosomal heterozygosity (Supplementary Table 3 and 4). Samples were
also excluded if they were considered to be outliers based on ethnicity inferred by principal
component analysis (PCA). PCA was performed using EIGENSOFT v4.2 with HapMap
phase 2 samples as reference populations on a subset of SNPs with a MAF > 0.05 and
filtered to minimise inter-marker LD (excluding the MHC region, 23 regions of high LD and
previously confirmed rheumatoid arthritis susceptibility regions) (Supplementary Figure 1).
Cryptic relatedness was assessed within each dataset by calculating identity-by-descent
(IBD) using PLINK v1.07 using the PCA SNP set. A single sample from any related pair
(PI_HAT > 0.1875) was removed from the analysis (informed by call rate). In addition IBD
was inferred across all six datasets to exclude cross-dataset related individuals
(Supplementary table 5). The genomic control inflation factor (λGC) was calculated within
each Immunochip dataset using SNPs included as deep replication for a study investigating
the genetic basis for reading and writing ability (submitted by J.C. Barrett). This set of SNPs
was filtered as described for the PCA SNP set, leaving a total of 1,469 SNPs distributed
evenly across the genome. The λGC for the datasets was estimated at; 1.07 (UK), 1.03 (US),
0.97 (SE-E), 0.94 (SE-U), 1.12 (NL), and 1.10 (ES). Using the same SNPs to estimate
λGC1000, where the factor is scaled to the equivalent of 1000 cases and 1000 controls, in
the Immunochip meta-analysis resulted in a rescaled λ of 1.02 (1.23 without rescaling).
All novel findings remained significantly associated when including gender and λGC as a
covariate in the analysis (Supplementary Table 15).
Immunochip meta-analysis
Association statistics were calculated in each dataset using logistic regression under an
additive model (SNPs coded 0, 1 or 2 with respect to minor allele dosage) and incorporating
the top ten principal components as covariates. Odds ratios and standard errors were
combined across the six datasets using inverse-variance meta-analysis assuming a fixed
effect.
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Independent effects
Initial evidence for secondary effects was assessed at each of the previously known and
newly identified loci using a forward stepwise logistic regression. The index SNP at each
region was included as a covariate and the association statistics re-calculated for the
remaining test SNPs. This process was repeated until no SNPs reached the minimum level of
significance. The criteria for declaring an independent effect was defined as: p-value <
5×10−4, not highly correlated with index SNP, the conditioned p-value must not differ
substantially from the unconditioned value. We next tested if the two-SNP fitted the risk at
the locus significantly better than the one-SNP model using a likelihood ratio test.
The effect estimates for each two-SNP haplotype was calculated by including indicator
variables for carriage of haplotypes. The indicator variables were constructed by phasing the
genotype data for each region satisfying the above criteria were phased using the SHAPEIT
algorithm18.
GWAS meta-analysis
GWAS case-controls collections were previously described1.Six collections were included
in the present study: BRASS, CANADA, EIRA, NARAC1, NARAC2, WTCCC. After
quality control and data filtering, the datasets were imputed using IMPUTE and haplotype-
phased HapMap Phase 2 European CEU founders as a reference panel19.
We used IBS estimates to remove related samples across the Immunochip and GWAS
collections, using GWAS genotype data instead of imputed data. In each of the twelve
collections, we selected a set of SNPs with missing-genotype rate<0.5%, minor allele
frequency>5% and Hardy-Weinberg PHWE>5×10−7. Then, we extracted SNPs that passed
these filters and were shared between the 12 collections. After further LD pruning and
resolving flipping issues, the data from the 12 collections were merged to calculate the IBS
statistics. When related samples were identified (siblings or duplicates), the sample from the
GWAS collection was removed to preferentially keep Immunochip data in the subsequent
association analyses. Filtering and IBS calculation were performed using PLINK20. Two
GWAS datasets, EIRA and NARAC1, were excluded because of strong overlap (>90%
rheumatoid arthritis cases) with the Immunochip SE-E and US collections, respectively.
This resulted in a total sample size of 13,838 rheumatoid arthritis cases and 33,742 controls,
distributed in 10 collections (Table 1).
The software SNPTEST v2.2 was used to conduct logistic regression analysis of rheumatoid
arthritis case-control status in each GWAS collection, conditioning upon the 5 first
eigenvectors from PCA analysis, and after excluding SNPs with low statistical information
(info score<0.7) or MAF<1%. We also excluded SNPs that were not represented in the
filtered Immunochip data. The λGC for the individual datasets was estimated at; 1.04
(BRASS), 1.02 (CANADA), 1.04 (NARAC2) and 1.05 (WTCCC). There was a slight
inflation in λGC in these cohorts when using the 1,469 SNPs included on Immunochip to
investigate the genetic basis of reading and writing ability; 1.11 (BRASS), 1.15
(CANADA), 1.07 (NARAC2) and 1.05 (WTCCC).
We conducted an inverse-variance weighted meta-analysis to combine the results across the
10 collections. We also computed Cochran’s Q statistics and I2 statistics to assess
heterogeneity across collections. Meta-analysis and heterogeneity statistics computation was
adapted from the MANTEL program21.
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Serological subtype statistical analysis
Multinomial logistic regression was applied to compute odds ratios (OR), 95% confidence
interval and p-values for association between the minor allele at every locus and either
ACPA-positive (ORACPA-positive) or ACPA-negative rheumatoid arthritis (ORACPA-negative)
assuming additivity on the log-odds scale (i.e. every locus was coded as 0,1 or 2
corresponding to the copy number of the minor allele). The minor allele was defined
according to the allele frequency in the total population, including cases and controls. To
test for differences between ORACPA-positive and ORACPA-negative, the linear combination
β+ - β−, where β+ is log (ORACPA-positive) and β− is log (ORACPA-negative) was calculated,
along with its standard error. This enables a p-value for the difference in association to be
calculated.
GRAIL analysis
We performed GRAIL analysis (http://www.broadinstitute.org/mpg/grail/grail.php) using
HG18 and Dec2006 PubMed datasets, default settings and the 46 genome-wide significant
rheumatoid arthritis susceptibility loci (most associated SNP) as seeds.
Interaction analysis
We performed an analysis of epistasis using the most significantly associated SNP from
each of the 46 loci (Table 2). Logistic regression was performed in PLINK to model
epistasis in each of the the six datasets with the top 10 PCs included as covariates. For each
pair of SNPs, the likelihood ratio test was employed to compute the p-value of the
interaction term for each dataset. Epistasis results were combined using METAL and
Bonferroni corrected.
eQTL analysis
eQTL analysis was done on the peripheral blood of 1,469 unrelated individuals (1,240
samples run on the Illumina HT12v3 platform, 229 samples run on the Illumina H8v2
platform) from the United Kingdom and the Netherlands. Details of the eQTL analysis have
been previously described22 . In short, we assessed the effect of all rheumatoid arthritis
associated SNPs (Table 2) on expression of genes, located within 250kb left and right from
the SNP (cis eQTLs).
All individuals from the eQTL study were genotyped on Illumina Hap300K platform and
then imputed to HapMap 2 using Impute 2.0 software. Since not all SNPs from Illumina
Immunochip platform were genotyped or imputed on the 1,469 eQTL samples, we used the
following strategy (Supplementary Figure 5): First, we investigated whether the SNP is
present in the eQTL data and had passed the QC for eQTL mapping (MAF >= 5%, HWE P-
value >= 0.001, call rate >= 95%). From 50 rheumatoid arthritis-SNPs, 26 were present in
HapMap imputed datasets and were directly assessed for eQTL effects (Supplementary
Table 13). For the other 24 SNPs, not present in our HapMap imputed data, we checked
whether the rheumatoid arthritis-SNP was available in 1000 genomes database. If so, we
queried all SNPs within 10MB of the rheumatoid arthritis-SNP that were also present in the
eQTL data and would pass eQTL QC measures, and picked the SNP with the highest LD
present in HapMap after QC. The threshold of r2>0.8 for the LD was used. For 12 SNPs, no
proxy was available with our criteria, and these SNPs were not included in the eQTL
analysis. For the remaining 12 SNPs the best proxy SNP is included to the eQTL table
(Supplementary Figure 5).
We also performed a cis-eQTL analysis for the top associated gene expression probe, as well
as two conditional analyses: (1) conditioning on the effect of the rheumatoid arthritis-SNP
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(gSNP), and (2) conditioning on the effect of the top eQTL SNP (eSNP) (Supplementary
Table 13).
The rheumatoid arthritis associated SNP was labelled as having a primary effect on gene
expression if it was either the top eQTL in the locus, or was a good proxy of top eQTL SNP
(r2>8). It was labelled as an independent eQTL if it showed an effect after conditioning on
the primary eQTL. From 20 rheumatoid arthritis SNPs, that showed an eQTL effect, 13 had
either an independent or primary eQTL effect on one or more probes (22 SNP-probe
combinations). A further 7 SNPs were not significant after the conditioning of the strongest
eQTL signal in the locus, suggesting that they are not primary eQTLs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plot of association statistics highlighting all autosomal loci associated to
rheumatoid arthritis in the study
P values of association to ACPA positive rheumatoid arthritis from the meta-analysis of the
Immunochip and GWAS data are shown. Known and new rheumatoid arthritis associated
loci are shown in red and black respectively. Three associated loci (identified by a *) only
reach P<5×10−8 when ACPA positive and ACPA negative cases are included in the analysis.
The dashed grey line indicates genome-wide significance (P=5×10−8).
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Table 1
Sample Collections
Rheumatoid arthritis cases and controls for the Immunochip analysis were assembled from a number of
different studies from 6 centres across 5 countries (online methods). Genotype data for additional samples
analysed in previously published rheumatoid arthritis ACPA positive GWAS were available from 4 studies.
Rheumatoid arthritis cases were classified as anti citrullinated peptide antigen (ACPA) positive and ACPA
negative. F:M = female: male.
Collection Cases Controls
All % Female ACPA + ACPA − % Female
Immunochip UK 3870 74 2406 1000 8430 53
Swedish EIRA 2762 70 1762 987 1940 73
US 2536 75 1803 593 2134 65
Dutch 648 66 330 301 2004 42
Swedish Umea 852 70 524 242 963 69
Spanish 807 74 397 216 399 65
TOTAL 11475 73 7222 3339 15870 57
GWAS BRASS (US) 479 82 479 - 1627 45
Canada 586 76 586 - 1553 54
NARAC2 (US) 746 48 746 - 6567 49
WTCCC (UK) 552 74 552 - 8125 46
TOTAL 2363 68 2363 - 17872 48
TOTAL 13838 72 9585 3297 33742 52
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Table 2
Non-HLA loci associated with rheumatoid arthritis at genome-wide significance level
Novel loci are shown with either the best SNP on Immunochip (Table 2a), if <5×10−8, or from the most
associated SNP from the combined analysis of GWAS and Immunochip data (Table 2b).
SNP Gene Chr MAF Risk
allele
P OR LD region r2>0.9* Region size Localization of
LD region (r2>0.9) relative to nearest genes
Novel loci on Immunochip
rs34536443b TYK2 19p13 0.04 G 2.3 × 10−14 0.62 10,427,721-
10,492,274
64.55 kb 47.96 kb 5′ to exon 13 of RAVER1; complete
ICAM3; complete TYK2
rs13397b IRAK1 Xq28 0.12 A 1.2 × 10−12 1.27 153,196,345-
153,248,248
51.9kp 5′ to exon 2 of TMEM187; HCFC1; 25 kb 3′
of
IRAK1
rs8026898b TLE3 # 15q23 0.29 A 1.4 × 10−10 1.17 69,984,462-
70,010,647
26.19 kb 329.48 kb 3′ of TLE3
rs8043085b RASGRP1 15q14 0.25 A 1.4 × 10−10 1.17 38,828,140-
38,844,106
15.97 kb Intron 2 of RASGRP1;
rs2240336b PADI4 1p36 0.42 A 5.9 × 10−09 0.88 17,673,102-
17,674,402
1.30 kb Intron 9 PADI4
rs8192284a
(rs2228145)
IL6R 1q21 0.42 C 1.3 × 10−08 0.9 154,418,749-
154,428,283
9.54 kb Intron 6 to intron 9 of IL6R
rs13330176b IRF8 16q24 0.22 A 4.0 × 10−08 1.15 86,016,026-
86,019,087
3.06 kb 59.83 kb 3′ of IRF8
Novel loci adding GWAS data
rs12764378d ARID5B # 10q21 0.23 A 4.5 × 10−10 1.14 63,786,554-
63,800,004
13.45 kb Intron 4 of ARID5B
rs9979383c RUNX1# 21q22 0.36 G 5.0 × 10−10 0.9 36,712,588-
36,715,761
3.17 kb 5′ region of RUNX1
rs12936409/
rs2872507c
IKZF3 17q12 0.47 A 2.8 × 10−09 1.1 37,912,377-
38,080,912
168.54 kb IKZF3;GSDMB; Intron 1 to 164.92 kb 3′ of
ORMDL3
rs883220d POU3F1# 1p34 0.26 A 2.1 × 10−08 0.89 38,614,867-
38,644,861
30.00 kb 102.42 kb 5′ of POU3F1
rs2834512d RCAN1 # 21q22 0.12 A 2.1 × 10−08 0.86 35,909,625-
35,930,915
21.29 kb Intron 1 of RCAN1
rs595158c CD5 11q12 0.49 C 3.4 × 10−08 1.09 60,888,001-
60,922,634
34.63 kb Intron 5 to 27.31 kb 3′ of CD5; Intron 1 to 9.73
kb 3′of VPS37C
rs2275806d GATA3 # 10p14 0.41 G 4.6 × 10−08 1.11 8,095,340-
8,097,368
2.03 kb 227bp 5′ to exon 2 of GATA3
Known loci on Immunochip
rs2476601b PTPN22 1p13 0.09 A 7.5 × 10−77 1.78 114,303,808-
114,377,568
73.76 kb Complete RSBN1; Exon 14 to 52.62 kb 3′ of
PTPN22
rs71624119a ANKRD55 5q11 0.25 A 5.6 × 10−20 0.81 55,440,730-
55,442,249
1.52 kb Intron 6 of ANKRD55
rs6920220b TNFAIP3 6q23 0.2 A 2.3 × 10−13 1.2 137,959,235-
138,006,504
47.27 kb 181.85 kb 5′ of TNFAIP3
rs932036a RBPJ 4p15 0.3 A 2.0 × 10−10 1.14 26,085,480-
26,128,710
43.23 kb 36.37 kb 5′ of RBPJ
rs59466457b CCR6 6q27 0.44 A 2.7 × 10−10 1.15 167,526,096-
167,540,842
14.75 kb Intron 1 of CCR6
rs13426947a STAT4 2q32 0.19 A 7.2 × 10−10 1.15 191,900,449-
191,935,804
35.36 kb Intron 5 to 18 of STAT4
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SNP Gene Chr MAF Risk
allele
P OR LD region r2>0.9* Region size Localization of
LD region (r2>0.9) relative to nearest genes
rs2812378b CCL21 9p13 0.34 G 7.2 × 10−10 1.15 34,707,373-
34,710,338
2.97 kb CCL21
rs6032662b CD40 20q13 0.24 G 1.4 × 10−09 0.86 44,730,245-
44,747,947
17.70 kb 16.67 kb 5′ to intron 1 of CD40
rs2843401b MMEL1 1p36 0.33 A 6.6 × 10−09 0.87 2,516,781-
2,709,164
192.38 kb Complete MMEL1,C1ORF93; TTC34
rs10209110a AFF3 2q11 0.49 A 1.1 × 10−08 0.9 100,640,432-
100,730,111
89.68 kb 5′ region to intron 2 of AFF3
rs34695944b REL 2p16 0.37 G 2.6 × 10−08 1.13 61,072,664-
61,164,331
91.67 kb Complete REL
rs11571302b CTLA4 2q33 0.48 A 4.5 × 10−08 0.89 204,738,919-
204,745,003
6.08 kb 236bp 3′ of CTLA4; 56.47 kb 5′ of ICOS;
rs39984a GIN1 5q21 0.32 A 9.3 × 10−08 0.88 102,595,778-
102,625,335
29.56 kb Intron 1 to 10.97 kb 3′
of C5orf30; 139.92 kb 5′of GIN1
rs35677470a DNASE1L3 3p14 0.08 A 1.7 × 10−07 1.19 58,181,499-
58,183,636
2.14 kb Exon 8 to intron 9 of DNASE1L3; 134.97 kb
5′
of PXK
rs3807306b IRF5 7q32 0.49 C 1.9 × 10−07 0.89 128,580,680-
128,580,680
1bp Intron 1 of IRF5
rs3218251b IL2RB 22q12 0.25 A 1.9 × 10−07 1.13 37,544,245-
37,545,505
1.26 kb Intron 1 of IL2RB
rs4938573b DDX6 11q23 0.18 G 5.3 × 10−07 0.87 118,662,993-
118,745,884
82.89 kb Complete SETP16; 1.14 kb 5′ of DDX6
rs6546146b SPRED2 2p14 0.38 A 8.0 × 10−07 0.9 65,556,324-
65,598,300
41.98 kb Intron 1 to intron 4 of SPRED2
rs629326b TAGAP 6q25 0.41 C 1.1 × 10−06 0.9 159,489,791-
159,496,713
6.92 kb 23.61 kb 5′ of TAGAP
rs10739580b TRAF1 9q33 0.33 G 1.7 × 10−06 1.12 123,640,500-
123,708,286
67.79 kb Complete TRAF1
rs10795791a IL2RA 10p15 0.4 G 3.0 × 10−06 1.09 6,106,266-
6,108,340
2.08 kb 1.93 kb 5′ of IL2RA
rs4840565a BLK 8p23 0.27 G 3.9 × 10−06 1.1 11,338,383-
11,352,485
14.10 kb 13.13 kb 5′ to intron 1 of BLK
rs798000b CD2 1p13 0.34 G 6.2 × 10−06 1.11 117,280,696-
117,280,696
1bp 16.31 kb 5′ of CD2
rs1980422f CD28 2q33 0.23 G 8.7 × 10−06 1.12 204,610,004-
204,634,569
24.57 kb 7.45 kb 3′ of CD28; 97.94 kb 5′ of CTLA4
rs2014863a PTPRC 1q31 0.36 C 2.1 × 10−05 1.09 198,791,907-
198,810,008
18.10 kb 65.36 kb 3′ of PTPRC
rs10683701b KIF5A 12q13 0.33 - 2.3 × 10−05 0.9 58,034,835-
58,105,094
70.26 kb snoU13;52.90 kb 5′ to intron 5 of OS9; 54.42
kb 3′ of KIF5A
rs947474a PRKCQ 10p15 0.17 G 2.5 × 10−05 0.9 6,390,450-
6,390,450
1bp 78.66 kb 3′ of PRKCQ
rs10494360b FCGR2A 1q23 0.12 G 3.0 × 10−05 1.14 161,463,876-
161,480,649
16.77 kb 11.34 kb 5′ to exon 5 of FCGR2A
rs6911690b PRDM1 6q21 0.12 G 1.2 × 10−04 0.87 106,435,981-
106,508,640
72.66 kb 25.55 kb 5′ of PRDM1
rs78560100a IL2-IL21 4q27 0.07 C 5.8 × 10−04 1.13 123,030,583-
123,503,591
473.01 kb KIAA1109;ADAD1;IL2; 30.19 kb 3′ of IL21
rs570676b TRAF6 11p12 0.38 A 2.1 × 10−03 0.93 36,486,064-
36,519,624
33.56 kb Intron 3 to 22.51 kb 3′ of TRAF6
a
Previously indentified loci are shown with the most significantly associated SNP on Immunochip (2c) indicates the data is from all rheumatoid
arthritis samples on Immunochip
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b
Previously indentified loci are shown with the most significantly associated SNP on Immunochip (2c) is data from Immunochip for ACPA
positive individuals
c
Previously indentified loci are shown with the most significantly associated SNP on Immunochip (2c) is data from adding GWAS samples and all
rheumatoid arthritis Immunochip data
d
Previously indentified loci are shown with the most significantly associated SNP on Immunochip (2c) is from ACPA positive Immunochip and
GWAS data.
*
co-ordinates based on GRCh37 assembly.
#
region not included for dense mapping on Immunochip.
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Table 3
Potential causal exonic SNPs located by Immunochip dense genotyping. Conservation is by phastCons17way,
study 99th percentile = 0.998; 95th percentile = 0.367. An essential splice site is a splice donor variant within
the 2 base pair region at the 5′ end of an intron. A splice site is a sequence variant within 1-3 base pairs of the
exon or 3-8 base pairs of the intron.
Chr POS Gene SNP MAF r2 with
lead
SNP
Location
Allele Amino acid
change
Polyphen SIFT Conservation
1 2,535,613 MMEL1 rs4648562 0.33 1 Essential splice site A - - - 1
1 114,377,568 PTPN22 rs2476601 0.12 lead Non-Synonymous coding A Arg620Trp benign tolerated 0.992
1 154,426,970 IL6R rs2228145 0.38 lead Non-Synonymous coding C Asp358Ala benign tolerated 0.008
3 58,183,636 DNASEIL3 rs35677470 0.09 lead Non-Synonymous coding A Arg206Cys probably
damaging
deleterious 0.992
11 60,893,235 CD5 rs2229177 0.47 0.96 Non-Synonymous coding C Ala471Val probably
damaging
deleterious 0.835
19 10,449,358 ICAM3 rs7258015 0.23 1 Non-Synonymous coding/
Splice site
C Arg115Gly benign tolerated 0
19 10,463,118 TYK2 rs34536443 0.04 lead Non-Synonymous coding G Pro1104Ala probably
damaging
deleterious 0.189
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